

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNS THE ENTIRE INTEREST AND THE GOODWILL		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
BioMimetic Therapeutics, Inc.	FORMERLY BioMimetics Pharmaceuticals, Inc.	01/04/2008	CORPORATION: DELAWARE
RECEIVING PARTY DATA			
Name:	Luitpold Pharmaceuticals, Inc.		
Street Address:	One Luitpold Drive		
City:	Shirley		
State/Country:	NEW YORK		
Postal Code:	11967		
Entity Type:	CORPORATION: NEW YORK		
PROPERTY NUMBERS Total: 2			
Property Type	Number	Word Mark	
Registration Number:	3197074	GEM	
Registration Number:	2981482	GEM 21S	
CORRESPONDENCE DATA			
Fax Number:	(202)312-9453		
	<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>		
Phone:	202-772-5354		
Email:	slyons@sheppardmullin.com		
Correspondent Name:	Stacy Lyons		
Address Line 1:	1300 I Street, N.W.,		
Address Line 2:	11th Floor East		
Address Line 4:	Washington, DISTRICT OF COLUMBIA 20005		
NAME OF SUBMITTER:	Stacy Lyons		
Signature:	/Stacy Lyons/		
Date:	01/07/2008		

OP \$65.00 3197074

Total Attachments: 8

source=GEM Executed Assignment Agreement#page1.tif
source=GEM Executed Assignment Agreement#page2.tif
source=GEM Executed Assignment Agreement#page3.tif
source=GEM Executed Assignment Agreement#page4.tif
source=GEM Executed Assignment Agreement#page5.tif
source=GEM Executed Assignment Agreement#page6.tif
source=GEM Executed Assignment Agreement#page7.tif
source=GEM Executed Assignment Agreement#page8.tif

ASSIGNMENT

THIS ASSIGNMENT is made as of the 4th day of January, 2008 between BioMimetic Therapeutics, Inc., by change of name from BioMimetics Pharmaceuticals, Inc., a Delaware corporation, having its principal place of business at 389-A Nichol Mill Lane, Franklin, Tennessee 37067, USA, (Assignor) and Luitpold Pharmaceuticals, Inc., a New York corporation, having its principal place of business at One Luitpold Drive, Shirley, New York 11967, USA (Assignee).

WHEREAS, Assignor has adopted and is the owner of the marks, as described, identified and listed in the attached Schedule A, (Marks);

WHEREAS, Assignor wishes to assign, grant and deliver exclusively to Assignee all rights, titles and interests of every kind and nature in and to the Marks, together with the goodwill of the business of Assignor to which the Marks, and all rights of action and claims, including actions and claims for past infringement, thereof;

NOW THEREFORE, in consideration of payment of the sum of \$10.00 and other good and valuable consideration, the receipt and sufficiency of which are acknowledged, the parties agree as follows:

Assignor assigns to the Assignee, and Assignee accepts, full right, title and interest in and to the Marks, together with the goodwill of the business symbolized by the Marks, and all rights of action and claims for past infringement.

Assignor agrees to execute any and all documents relating to the transfer and assignment of the Marks to Assignee for the purpose of meeting requirements for official recordation with any and all national and multi-national trademark authorities.

Now therefore, this agreement is assigned by the duly authorized Officers of the parties first set forth above.

For the Assignor:
BIOMIMETIC THERAPEUTICS, INC.

By: _____
Name: Samuel Lynch, D.M.D., D.M.Sc.
Title: President and CEO

For the Assignee:
LUITPOLD PHARMACEUTICALS, INC.

By: Mary Jane Helenek
Name: Mary Jane Helenek, R.Ph, M.S., M.B.A.
Title: President and CEO

[Signature Page for Assignment]

Schedule A

Country	Mark	App. #	App. Date	Reg. #	Reg. Date
Australia	GEM	838660	11/4/2004	838660	11/4/2004
Canada	GEM	1238816	11/26/2004	Pending	
China **	GEM	838660	11/4/2004	838660	11/4/2004
European Union	GEM	3713872	3/23/2004	3713872	7/27/2005
Hong Kong	GEM	300318438	11/12/2004	300318438	11/12/2004
Japan	GEM	838660	11/4/2004	838660	11/4/2004
Malaysia	GEM	2004/18802	12/2/2004	2004/18802	12/2/2004
New Zealand	GEM	721337	11/12/2004	721337	5/12/2005
Singapore	GEM	838660	11/4/2004	838660	11/4/2004
Taiwan	GEM	9305038	12/1/2004	01165837	8/1/2005
United States	GEM	76515877	5/21/2003	3197074	1/9/2007
WIPO	GEM	838660	11/4/2004	838660	11/4/2004
Australia *	GEM21A	838077	11/4/2004	838077	11/4/2004
Canada	GEM21A	1238814	11/26/2004	Pending	
China * **	GEM21A	838077	11/4/2004	838077	11/4/2004
European Union	GEM21A	3 713 881	3/23/2004	3713881	7/27/2005
Hong Kong	GEM21A	300318401		30318401	11/12/2004
Japan *	GEM21A	838077	11/4/2004	838077	11/4/2004
Malaysia	GEM21A	2004/18805	12/2/2004	2004/18805	12/2/2007
New Zealand	GEM21A	721340	11/12/2004	721340	5/12/2005
South Korea *	GEM21A	838077	11/4/2004	838077	11/4/2004
Taiwan	GEM21A	93056037	12/1/2004	01165836	8/1/2005
WIPO *	GEM21A	838077	11/4/2004	838077	11/4/2004
Australia	GEM21S	838072	11/4/2004	838072	11/4/2004
Canada	GEM21S	1238811	11/26/2004	688371	5/25/2007
China **	GEM21S	838072	11/4/2004	838072	11/4/2004
European Union	GEM21S	3 713 898	3/23/2004	3713898	7/27/2005


Country	Mark	App. #	App. Date	Reg. #	Reg. Date
Hong Kong	GEM21S	300318429	11/12/2004	300318429	11/12/2004
Japan	GEM21S	838072	11/4/2004	838072	11/4/2004
Malaysia	GEM21S	2004/18803	12/2/2004	2004/18803	12/2/2007
New Zealand	GEM21S	721338	11/12/2004	721338	5/12/2005
South Korea	GEM21S	838072	11/4/2004	838072	11/4/2004
Taiwan	GEM21S	93056035	12/1/2004	01165834	8/1/2005
United States	GEM21S	76515876	5/21/2003	2981482	8/2/2005
WIPO	GEM21S	838072	11/4/2004	838072	11/4/2004

* These registrations will fail when the USPTO notifies WIPO of the abandonment of the underlying U.S. application.

** BioMimetic makes no representations regarding the status of these trademarks, including whether China has recognized the WIPO deposit for these marks.

Now therefore, this agreement is assigned by the duly authorized Officers of the parties first set forth above.

For the Assignor:



Name: Samuel Lynch, D.M.D., D.M.Sc.

Title: President and CEO

For the Assignee:

Name:

Title:

[Signature Page for Assignment]

Now therefore, this agreement is assigned by the duly authorized Officers of the parties first set forth above.

For the Assignor:
BIOMIMETIC THERAPEUTICS, INC.

By: _____
Name: Samuel Lynch, D.M.D., D.M.Sc.
Title: President and CEO

For the Assignee:
LUITPOLD PHARMACEUTICALS, INC.

By: Mary Jane Helenek
Name: Mary Jane Helenek, R.Ph, M.S., M.B.A.
Title: President and CEO

[Signature Page for Assignment]

ACKNOWLEDGEMENT


STATE OF TENNESSEE)
COUNTY OF WILLIAMSON)

Before me, the undersigned, a Notary Public of the State and County aforesaid, personally appeared Samuel Lynch, with whom I am personally acquainted (or proved to me on the basis of satisfactory evidence), and who, upon oath, acknowledged himself to be President and Chief Executive Officer of BioMimetic Therapeutics, Inc., the within named bargainor, a Delaware corporation, and that he, as such President and Chief Executive Officer, being authorized so to do, executed the foregoing instrument for the purposes therein contained, by signing the name of the corporation by himself as President and Chief Executive Officer.

WITNESS my hand and official seal, this 4th day of January, 2008.



NOTARY PUBLIC



My Commission Expires:

12-12-2010

[Assignment Acknowledgement]

TRADEMARK
REEL: 003690 FRAME: 0901

ACKNOWLEDGEMENT

STATE OF NEW YORK

ss.:

COUNTY OF Suffolk

On the 4 day of January in the year 2008 before me, the undersigned, a Notary Public in and for said State, personally appeared Mary Jane Helenek, personally known to me or proved to me on the basis of satisfactory evidence to be the individual(s) whose name(s) is [is or are] subscribed to the within instrument and **acknowledged to me** that she [he or she or they] executed the same in her [his or her or their] capacity [capacity or capacities], and that by her [his or her or their] signature(s) on the instrument, the individual(s), or the person on behalf of which the individual(s) acted, executed the instrument.

Signature Denise M. Robinson

Name:
Notary Public

DENISE M. ROBINSON
Notary Public, State of New York
No. 01LE5023887
Qualified in Suffolk County
Commission Expires February 22, 2010

My Commission Expires:
2-22-2010

[Assignment Acknowledgement]

[Faint, illegible text]